Compare BBW & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBW | BNTC |
|---|---|---|
| Founded | 1997 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 473.7M | 396.3M |
| IPO Year | 2004 | 2020 |
| Metric | BBW | BNTC |
|---|---|---|
| Price | $25.85 | $9.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $43.00 | $24.33 |
| AVG Volume (30 Days) | ★ 534.3K | 161.5K |
| Earning Date | 08-27-2026 | 11-13-2026 |
| Dividend Yield | ★ 3.54% | N/A |
| EPS Growth | 5.00 | ★ 6.67 |
| EPS | ★ 2.16 | N/A |
| Revenue | ★ $357,866,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.33 | N/A |
| P/E Ratio | $12.04 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $24.15 | $8.52 |
| 52 Week High | $72.19 | $16.76 |
| Indicator | BBW | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 38.83 | 27.64 |
| Support Level | $24.15 | N/A |
| Resistance Level | $40.16 | $13.49 |
| Average True Range (ATR) | 1.06 | 0.80 |
| MACD | 0.32 | -0.13 |
| Stochastic Oscillator | 54.74 | 15.48 |
Build-A-Bear Workshop Inc is a U.S.-based specialty retailer of customized stuffed animals and related products. The company operates through three segments: Direct-to-consumer segment with key revenue, includes the operating activities of corporately-managed locations and other retail delivery operations in the U.S., Canada, U.K., Ireland, and two e-commerce sites, the international franchising segment includes royalties and product and fixture sales from other international operations under franchise agreements, and the commercial segment includes the transactions with other businesses, mainly comprised of licensing the intellectual properties for third-party use and wholesale activities.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.